Cargando…
Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970664/ https://www.ncbi.nlm.nih.gov/pubmed/33734339 http://dx.doi.org/10.1182/blood.2021010938 |
_version_ | 1783666456996610048 |
---|---|
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7970664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society of Hematology. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79706642021-03-19 Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915. Blood Erratum American Society of Hematology. Published by Elsevier Inc. 2021-03-18 2021-03-18 /pmc/articles/PMC7970664/ /pubmed/33734339 http://dx.doi.org/10.1182/blood.2021010938 Text en Copyright © 2021 American Society of Hematology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Erratum Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915. |
title | Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915. |
title_full | Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915. |
title_fullStr | Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915. |
title_full_unstemmed | Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915. |
title_short | Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915. |
title_sort | treon sp, castillo jj, skarbnik ap, et al. the btk inhibitor ibrutinib may protect against pulmonary injury in covid-19–infected patients. blood. 2020;135(21):1912–1915. |
topic | Erratum |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970664/ https://www.ncbi.nlm.nih.gov/pubmed/33734339 http://dx.doi.org/10.1182/blood.2021010938 |